Paliperidone palmitate (Xeplion®) 50 mg, 75 mg, 100 mg and 150 mg prolonged release suspension for injection
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000870
English
Authors' recommendations:
Paliperidone palmitate (Xeplion®) prolonged release suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone; and in selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, without prior stabilisation with oral treatment when psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/paliperidone%20palmitate%20%28Xeplion%29%20FAR1.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Isoxazoles
- Delayed-Action Preparations
- Schizophrenia
- Dose-Response Relationship, Drug
- Drug Administration Schedule
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.